NCT03725501View on ClinicalTrials.gov

Evaluation of the Safety and Efficacy of ALS-L1023 Administered in Combination With Ranibizumab in Patients With Wet-AMD

PHASE2CompletedINTERVENTIONAL

Enrollment

126

Participants

Timeline

Start Date

December 7, 2018

Primary Completion Date

June 22, 2021

Study Completion Date

June 22, 2021

Conditions

Age-Related Macular Degeneration

Interventions

DRUG

ALS-L1023

ALS-L1023 is an active fraction extracted from Melissa officinalis L. (Labiatae; lemon balm) leaves.

DRUG

Ranibizumab

LUCENTIS® (an anti-neovascular VEGF-A inhibitor) 0.5 mg, intravitreal injection

OTHER

Placebo

Control group for comparison with oral administration of ALS-L1023

Trial Locations (1)

34015

AngioLab, Inc., Daejeon

All Listed Sponsors

lead

AngioLab, Inc.

INDUSTRY

NCT03725501 - Evaluation of the Safety and Efficacy of ALS-L1023 Administered in Combination With Ranibizumab in Patients With Wet-AMD | Biotech Hunter | Biotech Hunter